Phathom Pharmaceuticals (PHAT) Assets Average (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Assets Average data on file, last reported at $282.1 million in Q1 2026.

• Assets Average for Q1 2026 came in at $282.1 million, down 16.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $282.1 million (down 16.1% YoY), and the FY2025 annual result was $318.7 million, down 19.53% from the prior year.
• Assets Average climbed to $282.1 million in Q1 2026 per PHAT's latest filing, from $249.7 million in the prior quarter.
• Over five years, Assets Average peaked at $385.2 million in Q1 2024 and troughed at $154.4 million in Q1 2023.
• A 5-year average of $266.0 million and a median of $251.0 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average slumped 37.49% in 2022, then soared 149.45% in 2024.
• A 5-year view of Assets Average shows it stood at $183.4 million in 2022, then jumped by 77.46% to $325.4 million in 2023, then climbed by 17.6% to $382.7 million in 2024, then sank by 34.74% to $249.7 million in 2025, then grew by 12.98% to $282.1 million in 2026.
• Business Quant data shows PHAT's Assets Average at $282.1 million in Q1 2026, $249.7 million in Q4 2025, and $245.3 million in Q3 2025.